Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adenovirus serotype 26-expressing HPV16 vaccine JNJ-63682918

A prime cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus serotype 26 (Ad26) encoding the oncogenic human papillomavirus 16 (HPV16), with potential immunostimulating and antineoplastic activities. Upon intramuscular administration of Ad26-expressing HPV16 vaccine JNJ-63682918, the adenovirus infects and expresses HPV16. The expressed proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 antigens, thereby inducing tumor cell lysis. HPV16 infection plays a key role in the development of a variety of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Ad26-expressing HPV16 vaccine JNJ-63682918
Ad26.HPV16 JNJ-63682918
adenovirus serotype 26-human papillomavirus 16 JNJ-63682918
monovalent HPV16 Ad26-vectored vaccine JNJ-63682918
Code name:JNJ 63682918
JNJ-63682918
JNJ63682918
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search